Stock FATE FATE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Fate Therapeutics, Inc.

Equities

FATE

US31189P1021

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
3.8 USD -1.81% Intraday chart for Fate Therapeutics, Inc. -20.67% +1.60%
Apr. 22 Fate Therapeutics, Inc. Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting CI
Mar. 21 Fate Therapeutics, Inc. announced that it has received $19.996366 million in funding from Redmile Group, LLC CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
GL
Fate Therapeutics Reports New Employee Inducement Award under Nasdaq Listing Rule 5635(4)
AQ
Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
GL
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
GL
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
GL
Fate Therapeutics Reports New Employee Inducement Award under Nasdaq Listing Rule 5635(4)
AQ
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
GL
Fate Therapeutics to Present at Upcoming March Investor Conferences
AQ
Fate Therapeutics to Present at Upcoming March Investor Conferences
GL
Fate Therapeutics: Q4 Earnings Snapshot
AQ
Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
GL
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results
GL
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
GL
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
AQ
Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors
GL
Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors
AQ
Radionetics Oncology Raises $52.5 Million Series A to Advance First-in-Class Radiopharmaceutical Pipeline and Announces the Appointment of Industry Leader, Paul Grayson, as CEO
AQ
Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Fate Therapeutics: Q3 Earnings Snapshot
AQ
Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. FATE Stock
  4. News Fate Therapeutics, Inc.
  5. Press Releases